Chemotherapy in metastatic malignant triton tumor: Report on two cases

Thoennissen,N. H.; Schliemann,C.; Brunnberg,U.; Schmidt,E.; Staebler,A.; Stegger,L.; Bremer,C.; Schleicher,C.; Mesters,R. M.; Müller-Tidow,C.; Berdel,W. E.

doi:10.3892/or.18.4.763

Chemotherapy in metastatic malignant triton tumor: Report on two cases

Authors:
- N. H. Thoennissen
- C. Schliemann
- U. Brunnberg
- E. Schmidt
- A. Staebler
- L. Stegger
- C. Bremer
- C. Schleicher
- R. M. Mesters
- C. Müller-Tidow
- W. E. Berdel
View Affiliations

Affiliations: Department of Medicine, Hematology and Oncology, University of Münster, D-48149 Münster, Germany. n.thoennissen@gmx.de
Published online on: October 1, 2007 https://doi.org/10.3892/or.18.4.763
Pages: 763-767

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant triton tumor (MTT) is a rare, highly malignant nerve sheath tumor with rhabdomyoblastic differentiation. Initial debulking surgery followed by adjuvant therapy is the current treatment of choice, but has very limited efficacy when optimal cytoreduction is not achieved by surgical procedure. Neoadjuvant therapy for MTT, to potentially facilitate subsequent surgery, eradicate micrometastatic lesions and, therefore, improve the therapeutical outcome, has never before been presented in literature. Here, we report on the multimodal management of two cases of advanced and metastatic MTT. Treatment modalities involved neoadjuvant and adjuvant chemotherapy, surgical resection, and radiation. In both cases, integrated Positron Emission Tomography/Computed Tomography (PET/CT) emerged as an important diagnostic tool for the reliable assessment of MTT response and metabolic remission.